| Name | Title | Contact Details |
|---|
The all-in-one digital solution for gut health and disease. We`re helping people feel better, while lowering their cost of care. At Vivante, we`re taking on digestive disease because an astonishing 70 million people in the US are affected—that`s twice the number with diabetes and more than many other chronic conditions combined. Unlike other chronic conditions, though, digestive diseases are often untreated or misdiagnosed...because of stigma. Over half of adults with digestive trouble admit they haven`t even consulted a provider about their symptoms. This is unfortunate because chronic digestive symptoms take a toll on home life, work performance, romance, and even simple social events. And digestive disease is expensive! For most companies, GI claims are the #2 healthcare expense, second only to cancer. Specialty drugs for inflammatory bowel disease can run $70k per year for just ONE employee. Now is the time for employers and health plans to address digestive health, while at the same time providing REAL help to the millions who are struggling and don`t know where to turn. Our all-in-one digital program, GIThrive®, empowers people—through brilliant technology and advanced science—to spend less time worrying about their digestive symptoms and more time living life. A wonderful byproduct of the GIThrive success is reduced medical and Rx drug spending for employers, health plans and individuals.
Versartis, Inc. (NASDAQ: VSAR) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. The company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. Versartis` mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. Versartis is well-positioned to deliver a major innovation to the global growth hormone deficiency (GHD) market with the company`s most advanced clinical candidate, somavaratan. Somavaratan is a novel, long-acting form of recombinant human growth hormone that is in global late-stage clinical trials to treat GHD in children and adults. Twice-monthly somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance/adherence and treatment outcomes.
AbboMax is a San Jose, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Since 1965, Brown Medical Industries has manufactured quality, innovative orthopaedic products, including ingenious SEAL-TIGHT cast and bandage moisture protectors and the historically strong-selling Plastalume finger, arm and leg splints.
Mobile Help is a San Bernardino, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.